Sanofi (SNY) Non-Current Deferred Tax Liability (2009 - 2025)

Sanofi has disclosed Non-Current Deferred Tax Liability across 17 years of filings, most recently posting $1.9 billion for Q4 2025.

• Non-Current Deferred Tax Liability for Q4 2025 came in at $1.9 billion, down 16.21% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.9 billion (down 16.21% YoY), and the FY2025 annual result was $1.9 billion, down 16.21% from the prior year.
• Non-Current Deferred Tax Liability came in at $1.9 billion for Q4 2025 at Sanofi, roughly flat from $1.9 billion in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $2.3 billion in Q4 2024 to a low of $1.7 billion in Q2 2022.
• The 5-year median for Non-Current Deferred Tax Liability is $1.9 billion (2025), against an average of $2.0 billion.
• Across the five-year window, Non-Current Deferred Tax Liability decreased 17.96% in 2022 and grew 28.38% in 2023, its largest moves.
• Sanofi's Non-Current Deferred Tax Liability stood at $1.8 billion in 2021, then rose by 1.54% to $1.9 billion in 2022, then rose by 6.38% to $2.0 billion in 2023, then climbed by 15.84% to $2.3 billion in 2024, then dropped by 16.21% to $1.9 billion in 2025.
• The last three Non-Current Deferred Tax Liability figures came in at $1.9 billion (Q4 2025), $1.9 billion (Q2 2025), and $2.3 billion (Q4 2024), per Business Quant data.